Background
==========

Caesarean section in spinal anesthesia has become increasingly popular in recent years and is now a commonly performed surgical procedure. Regional anesthesia is performed in 80% of anesthetized patients compared to 20% who receive general anesthesia \[[@b1-medscimonit-19-993],[@b2-medscimonit-19-993]\]. While consciousness allows the patient to enjoy the early intimate contact with the newborn child (bonding), the procedure may be associated with various important problems \[[@b3-medscimonit-19-993]\]. Arterial hypotension and headache, insufficient or abundant anesthesia, and psychologic distress may be some of the adverse effects of regional anesthesia for caesarean section \[[@b4-medscimonit-19-993],[@b5-medscimonit-19-993]\].

A common problem in caesarean section is intra- and postoperative nausea and vomiting under regional anesthesia \[[@b6-medscimonit-19-993]--[@b8-medscimonit-19-993]\]. NV can happen during and after the birth and may affect the well-being of mother and family \[[@b9-medscimonit-19-993]\]. The well-being of patients may be severely compromised \[[@b10-medscimonit-19-993]\]; 72% of patients are afraid of NV \[[@b11-medscimonit-19-993]\] and 71% feel significant discomfort \[[@b12-medscimonit-19-993]\]. Critical anesthesiological complications such as airway obstruction, aspiration pneumonitis, and wound dehiscence are rare and mainly related to postoperative nausea and vomiting in general surgical patients \[[@b13-medscimonit-19-993],[@b14-medscimonit-19-993]\]. In addition to postoperative pain, NV is one of the most frequent anesthesiological complications. Previous reports and our observations suggest both nausea and vomiting as a frequent phenomenon, with incidences up to 80% \[[@b5-medscimonit-19-993],[@b9-medscimonit-19-993],[@b15-medscimonit-19-993],[@b16-medscimonit-19-993]\].

Necessary therapeutic measures, the use of personnel, and room and material resources represent an enormous economic burden and are being closely monitored by health system administrators \[[@b17-medscimonit-19-993]\]. Due to the complex pathophysiology, the treatment and prophylaxis of NV is difficult. To keep the costs low, alternative treatments like acupressure and acupuncture are used \[[@b8-medscimonit-19-993],[@b18-medscimonit-19-993]--[@b20-medscimonit-19-993]\]. The pharmacological interventions available include a wide range of drug medication, including dopamine and serotonin receptor antagonists, corticosteroids, antihistamines, sedatives, and anticholinergic drugs \[[@b9-medscimonit-19-993],[@b16-medscimonit-19-993],[@b21-medscimonit-19-993]\].

The major risk factor for nausea and vomiting during or after spinal anesthesia in cesarean section is arterial hypotension due to the blockade of the sympathetic nerve system \[[@b9-medscimonit-19-993]\]. NV may be influenced by hormonal changes during pregnancy, which alter the sphincter tone of the esophagus and the stomach and the activity of the small bowel and esophagus, as well as adverse effects of uterotonic drugs, intraoperative manipulation of the uterus, and/or psychological distress aggravated by insufficient or excessive anesthesia \[[@b22-medscimonit-19-993]--[@b24-medscimonit-19-993]\].

Previous studies have addressed the efficiency of different anti-emetics in terms of reduction of PONV risk in cesarean section patients, mostly using only 1 agent \[[@b9-medscimonit-19-993],[@b21-medscimonit-19-993]\]. In a recently published study, we were able to find a multimodal prophylactic regimen for breast surgical procedures \[[@b25-medscimonit-19-993]\]. There are several studies in spinal anesthesia indicating that multimodal prophylaxis is preferable to prevent NV, especially in caesarean section \[[@b5-medscimonit-19-993],[@b9-medscimonit-19-993],[@b21-medscimonit-19-993]\].

The goal of the present study was to investigate multimodal pharmacological approaches with tropisetron and metoclopramide (Group II) and dimenhydrinate and dexamethasone (Group III) compared to a mono therapy with tropisetron (Group IV) *versus* no prophylaxis (Group I) to prevent NV intra- and postoperatively in patients undergoing cesarean section under spinal anesthesia.

Material and Methods
====================

For statistical analysis, we created 4 groups:

1.  Group I: No prophylactic agents;

2.  Group II: Tropisetron 2 mg + Metoclopramide 20 mg prophylactically;

3.  Group III: Dimenhydrinate 31 mg and Dexamethasone 4 mg prophylactically;

4.  Group IV: Tropisetron 2 mg prophylactically.

The antiemetic efficacy of the 4 different treatments was evaluated in 308 patients undergoing cesarean section. We included 308 patients scheduled for cesarean section as a planned or non-urgent procedure. Not included were procedures using epidural anesthesia, emergency procedures and procedures using general anesthesia, systemically ill patients, parturients affected with gestosis, HELLP syndrome, and known allergies to the planned medication. Also excluded were patients under the age of 18.

After obtaining approval from the Institutional Review Board (Evangelian Deaconry Hospital Freiburg, Germany) and written informed patient consent, patients were randomly assigned to 1 of the 4 groups.

All patients were given premedication with midazolame 3.75 mg orally 1 hour before transfer to the operating theatre. Spinal anesthesia (SPA) was induced in left lateral position between L3/L4 with 0.5% hyperbaric bupivacaine. Dosage depended on the body height. Body height 150 cm resulted in 1.8 ml bupivacaine 0.5%; every 5 cm additional body height resulted in an additional 0.2 ml bupivacaine dosage. No opioids were used. After successful puncture, patients were brought in prone position, a Foley catheter was applied and the operating table was brought into a 20° left lateral position to circumvent vena cava compression syndrome. When the anesthetic effect reached the TH 4/5 segment, patients were kept in an anti-Trendelenburg position to stop further ascent. Systolic blood pressure was kept at a minimum of 100 mmHg with 2 ml doses of cafedrin-theodrenalin diluted 1:10. Cesarean section was carried out in standard surgical technique in all patients. After full development of the child, the anti-emetic prophylaxis was applied according to randomization. Further medication was oxytocin (3 units bolus, and 10 units in 500 cc 0.9% NaCl), antibiotic prophylaxis (1.5 g Uracid or 2 g Cefazolin in case of allergy to Penicillin). Postoperative pain management was carried out with piritramide and pethidine boluses. Events of nausea and/or vomiting were recorded in a special questionnaire 2 and 24 h postoperatively.

Data recorded consisted of: date of operation, age, ASA, duration of anesthesia and operative procedure, medication taken at home, intraoperative medication, level of SPA, NV risk factors, type of NV prophylaxis given, intraoperative complications, intraoperative NV according to the numeric rating scale (NRS) with 0 representing no NV and 10 the worst possible NV event, intraoperative fluid management, postoperative opioids, onset and degree of NV in minutes after the end of the operation and medication given, other postoperative complications, and overall patient satisfaction.

The primary outcome in this study was the incidence of nausea, emesis, or both during the operation and in the early (0--2 h) or late (2--24 h) postoperative period. Trained investigators recorded the number of episodes and the time of occurrence. In all intervals, patients scored the NV experience on a scale comparable to the numeric rating scale (NRS), where 0 represented no NV and 10 the worst possible NV event.

Patients were randomly assigned preoperatively to 1 of 4 groups with sealed opaque envelopes that were opened by the anesthetist before induction of anesthesia. Randomization resulted in 76 patients in Group I (no prophylaxis given), 82 patients in Group II (prophylactic agents Tropisetron and Metoclopramide), 79 patients in Group III (prophylactic agents Dimenhydrinate and Dexamethasone), and 71 patients in Group IV (prophylactic agent Tropisetron).

Anti-emetic therapy of patients exhibiting PONV in the early and late postoperative period (0--2 h and 2--24 h) was left to the discretion of the physician responsible for the ward, where all agents except the ones already used for anti-emetic prophylaxis could be taken into account.

Statistical analysis
--------------------

To assess the individual risk of the patients and the risk reduction through the anti-emetic prophylaxis, a multivariate statistical analysis was performed. The variables considered (eg, duration of the operation, events of hypotension) were used to build a statistical model with SAS/STAT (SAS Institute Inc., Cary, NC). During multiple steps, all factors with p\>0.05 were removed. The remaining factors significantly affected the observed endpoint, which was the incidence of nausea and vomiting. The degree of association of the considered factors and the endpoint were determined using odds ratios. Results were considered statistically significant at p\<0.05.

Results
=======

There were 308 patients who underwent randomization to 1 of the 4 groups: 76 patients in Group I (no prophylaxis given), 82 patients in Group II (prophylactic agents Tropisetron and Metoclopramide), 79 patients in Group III (prophylactic agents Dimenhydrinate and Dexamethasone), and 71 patients in Group IV (prophylactic agent Tropisetron).

Outcome data were complete for all 308 patients: 100% of the patients were female, 90.3% were non-smokers, 23.4% had a history of nausea and vomiting or motion sickness, and 56.8% received postoperative opioids. Intraoperative hypotension was recorded in 46.15% and all patients had a dermatome level TH4/5. There were no significant differences between groups ([Table 1](#t1-medscimonit-19-993){ref-type="table"}).

Groups were investigated regarding nausea and vomiting intraoperatively and postoperatively in the early (0--2 h) and late (2--24 h) postoperative period. The incidences of nausea and vomiting were summarized because the incidence of vomiting was rare and statistically non-significant.

Overall 165 (53.6%) patients out of 308 experienced intra- or postoperative nausea and vomiting ([Table 2](#t2-medscimonit-19-993){ref-type="table"}).

There were significant differences in incidence of NV between groups ([Figure 1](#f1-medscimonit-19-993){ref-type="fig"}).

Group II had the lowest incidence of intraoperative NV (26.8%) and Groups III and IV showed no significant differences. The relative incidence of IONV was 46.8% (Group 3) and 46.5% (Group 4).

Group I had the highest rate of patients experiencing IONV (64.5%) ([Tables 2](#t2-medscimonit-19-993){ref-type="table"} and [3](#t3-medscimonit-19-993){ref-type="table"}).

Compared to Group I (no medication), all prophylactic medication (Groups II, III, and IV) led to a significantly lower rate of IONV. Group II had the most effective prophylactic medication. The effect of medication of Group III and Group IV are roughly similar (an odds ratio of 1 means equality) ([Table 4](#t4-medscimonit-19-993){ref-type="table"}).

The difference between Group II and III and Group II and IV was also significant. The odds ratios (OR) of 0.42 and 0.42 emphasize the significantly lower incidence of IONV in Group II compared to Group III and Group IV.

In detail the results for intra and postoperative nausea and vomiting separately are mentioned.

Intraoperative nausea and vomiting
----------------------------------

Patients without any prophylaxis given experienced the most nausea intraoperatively (63.2%). Every prophylaxis given significantly lowered the incidence of nausea intraoperatively. The most effective prophylactic medication against intraoperative nausea was a combination of tropisetron and metoclopramide (25.6%) (Group II).

Intraoperative vomiting was also highest in Group I (15.8%) and was significantly lower in Group II (3.7%), Group III (8.9%), and Group IV (1.4%).

Postoperative nausea and vomiting
---------------------------------

In the early postoperative period (0--2 h) the incidence of nausea was highest in the non-treated group I (9.2%), and was lowered by prophylaxis in Group II (6.1%), Group III (5.1%), and group IV (4.2%). Differences were marginally significant.

There were no differences in the incidence of nausea in the late postoperative period (2--24 h) between groups (1% in Groups I--III, and 3% in Group IV).

Postoperative vomiting was rare: 3% in Group I and none of the patients in the treatment groups experienced vomiting postoperatively.

The major influence from a statistical point of view seems to have been the type of medication given. The medication in Group II is preferable to medication of Groups III and IV.

There are no statistical differences between the effect of medication of Groups III and IV.

The other risk factors additionally investigated did not show any significant differences. There was no risk factor that influenced all groups.

The median of symptom strength among the symptomatic patients was 5.5 and the mean number of episodes was 1.5.

Discussion
==========

The aim of this study was to find a highly efficient anti-emetic regimen and anesthetic procedure to reduce the incidence of intra- and postoperative nausea and vomiting in 308 female patients exposed to cesarean section surgery under spinal anaesthesia. The study was conducted on the background that an optimal perioperative patient comfort is of outstanding interest and NV with an average incidence of 30% is rated as one of the most undesirable events in the context of surgery and anesthesia \[[@b26-medscimonit-19-993]--[@b28-medscimonit-19-993]\].

Therefore, every attempt should be made, especially in the context of birth, to avoid this complication, which is not only an unpleasant adverse effect, but also may cause severe complications such as wound dehiscence, dehydration, aspiration, or pneumothorax \[[@b13-medscimonit-19-993],[@b14-medscimonit-19-993]\].

We compared combinations (tropisetron/metoclopramide and dimenhydrinate/dexamethasone) and a single-drug regimen (tropisetron) of known and effective drugs against no prophylaxis to find the best prophylactic treatment for intraoperative and postoperative nausea and vomiting. All anti-emetic agents used in this study have been previously extensively investigated and their efficacy in terms of NV reduction has been proven \[[@b29-medscimonit-19-993]--[@b35-medscimonit-19-993]\].

In our patients, intraoperative nausea and vomiting was the main problem (60% in the untreated group). Postoperative events of nausea and vomiting were low (9%) even in the untreated group. This finding agrees with results of other investigations, which showed the main onsets of discomfort during the procedure, with incidences of up to 80% \[[@b15-medscimonit-19-993]\]. Causes for the high incidence of NV may be intraoperative hypotension, reduced cardiac output due to vena cava compression, uterotonic drugs such as oxytocin and particularly Methergine, exteriorization and manipulation of the uterus, intestines, and peritoneum, as well as psychological distress, although underlying pathomechanisms are not fully understood in all details \[[@b24-medscimonit-19-993],[@b36-medscimonit-19-993],[@b37-medscimonit-19-993]\].

In addition, pregnant women *per se* have a predisposition for NV -- 20% of pregnant women have emesis gravidarum and 10% have hyperemesis gravidarum, perhaps due to high levels of HCG, obesitas, reduced gastroesophageal tone, and psychological changes \[[@b38-medscimonit-19-993]\].

Prophylactic agents
-------------------

Tropisetron was one of the prophylactic anti-emetic agents used in this study. It belongs to the group of 5-HT3- or serotonin antagonists acting in the chemoreceptive trigger zone \[[@b39-medscimonit-19-993]\]. These substances block the vagal stimulated emetogen effect of serotonin. Efficacy of serotonin antagonists in prevention and therapy of PONV has been extensively proven in numerous investigations \[[@b30-medscimonit-19-993]\]. Primarily developed for the treatment of chemotherapy-induced nausea and vomiting, they now play an important role in modern anesthesia. They are considered as relatively safe -- single-dose adverse effects are mostly limited to headache, tachycardia, and sedation \[[@b29-medscimonit-19-993]\]. According to the investigations of Apfel and others, serotonin antagonists are primarily used as second- or third-line drugs in preventing or treating PONV \[[@b32-medscimonit-19-993],[@b40-medscimonit-19-993]\]. The relative expensiveness of these drugs may limit general use, considering increasing economic constraints in most health care systems \[[@b40-medscimonit-19-993],[@b41-medscimonit-19-993]\].

Dexamethasone was also used as an anti-emetic in this study. Eberhart et al. showed that dexamethasone is as effective as other established anti-emetic drugs in PONV prophylaxis and therapy \[[@b42-medscimonit-19-993]\]. This was confirmed by the multi-center trial of Apfel et al, which demonstrated that the anti-emetic effects of dexamethasone, droperidol, and ondansetron are comparable \[[@b32-medscimonit-19-993]\]. The underlying mechanism of action is not entirely clear and needs further investigation \[[@b43-medscimonit-19-993]\]. Dexamethasone has a delayed onset of action, but a long-lasting effect \[[@b44-medscimonit-19-993]\]. In addition, it is known to lower surgery-induced inflammation \[[@b45-medscimonit-19-993]\]. No severe adverse effects are known with this drug and it is reasonably priced \[[@b42-medscimonit-19-993]\]. Dexamethasone is also well established in the context of chemotherapy induced nausea and vomiting \[[@b46-medscimonit-19-993],[@b47-medscimonit-19-993]\]; low doses provide a sufficient anti-emetic effect \[[@b45-medscimonit-19-993]\].

Dimenhydrinate was another anti-emetic agent used in this study and belongs to the group of antihistamines acting on histamine receptors in the chemoreceptor trigger zone \[[@b40-medscimonit-19-993],[@b48-medscimonit-19-993]\]. It is, for example, very successfully used for the treatment of motion sickness \[[@b49-medscimonit-19-993],[@b50-medscimonit-19-993]\]. Its efficacy has also been proven in the context of PONV prophylaxis and therapy, although with fewer studies. Its use in anesthesia so far appears to be less frequent, although it is safe and reasonably priced \[[@b40-medscimonit-19-993],[@b51-medscimonit-19-993]\]. One major drawback may be sedation caused by this agent \[[@b50-medscimonit-19-993]\].

Metoclopramide antagonizes dopamine effects in the chemoreceptor trigger zone in the brainstem. Adverse effects include sedation and in some cases agitation and extrapyramidal effects. Drugs of these group may be problematic due to the profile of adverse effects, which include not only sedation, but also Parkinson symptoms (tremor, rigor, akinesis) \[[@b34-medscimonit-19-993]\] and severe arrhythmias (torsade de pointes), which is why droperidol, one of the oldest and best established anti-emetics and also used in the context of PONV, was withdrawn from the German market, but subsequently relaunched \[[@b29-medscimonit-19-993]\]. Several investigations have shown the efficacy of metoclopramide in terms of PONV prophylaxis and therapy when it is used in high doses or in combination with other antiemetic drugs like corticoids \[[@b52-medscimonit-19-993]\].

Numerous investigations have shown that both metoclopramide and tropisetron may reduce intra- and postoperative nausea and vomiting in parturients with spinal anesthesia, dexamethasone reduces intraoperative nausea and vomiting, and antihistamines reduce postoperative nausea and vomiting, although data for the latter group of substances are comparatively sparse \[[@b5-medscimonit-19-993],[@b21-medscimonit-19-993]\].

Previous studies in other surgical procedures, such as the multicenter trial of Apfel et al. in 2004, have also shown that anti-emetics in combination add their individual contribution to NV reduction and, therefore, are preferable, particularly in high-risk patients \[[@b31-medscimonit-19-993],[@b48-medscimonit-19-993],[@b53-medscimonit-19-993]\]. Apfel et al. demonstrated that in a combination of anti-emetics, each drug has an additional proportional effect, which means that a double or triple combination is twice or three times as effective as a single drug. Comparison of ondansetron, dexamethasone, and droperidol, for example, shows a step-wise NV risk reduction of 30% by each individual drug \[[@b48-medscimonit-19-993]\], which, however, was assessed in the context of general anesthesia.

In this study, we chose 2 anti-emetic combinations (tropisetron/metoclopramide and dimenhydrinate/dexamethasone) and a single-drug regimen consisting of tropisetron in comparison to no prophylaxis. With the combination dimenhydrinate/dexamethasone, we had an excellent anti-emetic experience in a previous investigation with patients undergoing elective breast surgery under general anesthesia. On the other hand, preliminary investigations have shown that tropisetron and/or metoclopramide have a good anti-emetic effect in parturient patients with spinal anesthesia. Previous experiences have also shown that these drugs were in part randomly used and, therefore, not in a controlled, firmly-established prophylaxis.

In our study, double prophylaxis with metoclopramide/tropisetron was most effective regimen and reduced nausea to 25.6% intraoperatively and to 6.1% 1--2 h and 1% 2--24 h postoperatively. Vomiting was 3.66% lower intraoperatively. In contrast, dimenhydrinate/dexamethasone prophylaxis significantly decreased the incidence of nausea intraoperatively to 44.2% and 1--2 hrs postoperatively to 5.06% and to 1% 2--24 h postoperatively, and was just as effective as the single prophylaxis with tropisetron (45.07% intraoperatively, 4.23% 0--2 h postoperatively, 3% 2--24 h, and 1.41% intraoperatively).

In the postoperative period, there was no significant difference in nausea between the treatment groups. Vomiting, in contrast to nausea, is rare intra- and postoperatively, and was lowered by approximately the same extent in the untreated group as in the treated groups.

Why are the different anti-emetic regimes so different in their effects? One aspect to be considered is the surgical procedure itself, which is associated with an exteriorization of the uterus and often manipulation of the peritoneum and bowel, thus irritating receptors (e.g., 5-HT3 and 5-HT4 type) and the vagal nerve system, thus causing nausea and vomiting \[[@b54-medscimonit-19-993]\]. In contrast to dexamethasone and dimenhydrinate, both tropisetron and metoclopramide have a direct and pronounced effect on the bowel and the upper gastrointestinal system, respectively \[[@b30-medscimonit-19-993],[@b49-medscimonit-19-993]\].

Tropisetron interacts with 5-HT3 and 5-HT4 receptors in the bowel, thus influencing motility and preventing serotonin-mediated nausea and vomiting (e.g., induced by surgical manipulation of the bowel and intestines) \[[@b11-medscimonit-19-993],[@b30-medscimonit-19-993]\]. Metoclopramide increases forward motility of the upper gastrointestinal system, thus preventing reflux and regurgitation, but also interacts with 5 HT3 and 5 HT4 receptors as tropisetron and may additionally reduce nausea and vomiting by this mechanism \[[@b43-medscimonit-19-993],[@b55-medscimonit-19-993]\]. Both agents interact via receptors at the chemoreceptor trigger zone, thus accentuating their anti-emetic effect \[[@b11-medscimonit-19-993],[@b43-medscimonit-19-993]\].

Unfortunately, in most cases anti-emetic medication is given as a treatment, so the patients and their family are exposed to the unpleasant experience of intraoperative NV or PONV. Our results suggest that prophylaxis as applied in this study can certainly reduce the onset of intraoperative NV and PONV and the associated discomfort. Both the mono- and combination therapy with well-known and safe drugs are efficient ways of doing this.

In terms of costs and adverse effect profile, the anti-emetic combination of tropisetron and metoclopramide appears to be superior and preferable. Except for sedation, no substantial adverse effect was observed in any of our patients. Current costs for metoclopramide/tropisetron prophylaxis are in a range of 0.15--0.8 Euros in our hospital, compared to for example, 0.25/1.2 Euros for dexamethasone/dimenhydrinate. Prices, however, may vary in different hospitals.

Although a triple anti-emetic prophylaxis may have further decreased NV and PONV incidence in this study, we did not test this due to increasing risk of significant adverse effects and is advised only in extremely high-risk patients.

Conclusions
===========

Our investigation in 308 patients experiencing cesarean section under spinal anaesthesia shows that intra- and postoperative nausea and vomiting can be significantly reduced by an anti-emetic prophylaxis combination of tropisetron 2 mg and metoclopramide 20 mg.

Therefore, this safe and reasonably priced combination should be preferred for use in preventing intraoperative NV and PONV in cesarean section patients under spinal anaesthesia.
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###### 

Patient characteristics, no influence on outcome, tested by Chi-Square independence test.

  Group           Age    Non-smoker %   PONV/motion sickness %   Length of surgery min.   Postopopioids %   Introphypotension %   Piritramid mg   Pethidin mg   Bradycadia \<50/min.   Oxytocin 3 I.E.   Oxytocin 10 I.E.   Dermatome
  --------------- ------ -------------- ------------------------ ------------------------ ----------------- --------------------- --------------- ------------- ---------------------- ----------------- ------------------ -----------
  I none (n=76)   33     86.8           27.6                     27.5                     50                47.4                  15.0            37.5          1.3                    92.1              93.8               TH 4/5
  TM (n=82)       33     91.5           20.7                     26.5                     68.3              45.1                  15.0            25.0          6.1                    93.6              92.7               TH 4/5
  III DD (n=79)   31     91.1           22.8                     25.0                     58.2              45.8                  15.0            50.0          5.1                    93.7              96.2               TH 4/5
  IV T (n=71)     33     91.5           22.5                     26.0                     50.7              46.5                  15.0            25.0          2.8                    94.4              94.4               TH 4/5
  p value         0.75   0.72           0.78                     0.74                     0.70              0.99                  0.83            0.76          0.99                   0.96              0.72               

###### 

Overall outcome of 308 patients intra- and postoperative in the early (0--2 h) and late (2--24 h) period, incidence of Nausea and/or vomiting.

  Group           Intraop      Early (0--2 h)   Late (2--24 h)   Total (intra-24 h)
  --------------- ------------ ---------------- ---------------- --------------------
  I none (n=76)   49 (64.5%)   7 (9.2%)         1 (1%)           57 (74.7%)
  II TM(n=82)     22 (26.8%)   5 (6.1%)         1 (1%)           28 (33.9%)
  III DD (n=79)   37 (46.8%)   4 (5.1%)         1 (1%)           42 (52.9%)
  IV T (n=71)     33 (46.5%)   3 (4.2%)         2 (3%)           38 (53.7%)

###### 

Intraoperative Nausea and Vomiting (IONV) and type of medication.

                                                          Intraoperative Nausa and Vomiting (IONV)           
  ------------------------------------------- ----------- ------------------------------------------ ------- ------
  Group I: No prophylaxis                     Incidence   27.0                                       49.0    76.0
  \%                                          35.5        64.5                                       100.0   
  Group II: Tropisetrone + Metoclopramid      Incidence   60.0                                       22.0    82.0
  \%                                          73.2        26.8                                       100.0   
  Group III: Dimenhydrinate + Dexamethasone   Incidence   42.0                                       37.0    79.0
  \%                                          53.2        46.8                                       100.0   
  Group IV: Tropisetrone                      Incidence   38.0                                       33.0    71.0
  \%                                          53.5        46.5                                       100.0   

###### 

Odds ratios: comparison of groups in pairs and p-values of chi-square test.

  Design   Group     Odds ratio   Lower KI    Upper KI   p-value Chi^2^-test                 
  -------- --------- ------------ ----------- ---------- --------------------- ------ ------ -------
  1        Group I   Group II                            4.95                  2.51   9.75   0.000
  2        Group I                Group III              2.06                  1.08   3.93   0.027
  3        Group I                            Group IV   2.09                  1.08   4.05   0.028
  4                  Group II     Group III              0.42                  0.22   0.80   0.008
  5                  Group II                 Group IV   0.42                  0.22   0.83   0.012
  6                               Group III   Group IV   1.01                  0.53   1.93   0.965
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